Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions - Wikidata - wikimedia - TriplyDB

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions

http://www.wikidata.org/entity/Q28262540

about

Malignant mesothelioma Meeting report: mode(s) of action of asbestos and related mineral fibers Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Soc Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions Factors that impact susceptibility to fiber-induced health effects Guidelines for the diagnosis and treatment of malignant pleural mesothelioma Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.Identification of novel markers for the diagnosis of malignant pleural mesothelioma.fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions.The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.Association of biomarker levels with severity of asbestos-related diseases Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma Asbestos burden predicts survival in pleural mesothelioma.Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Biomarkers for malignant pleural mesothelioma: current status.Future developments in the management of malignant pleural mesothelioma.Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.Soluble markers for diagnosis of malignant pleural mesothelioma.Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication.The challenge of prognostic markers in pleural mesothelioma.Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.A new anti-mesothelin antibody targets selectively the membrane-associated form.

P2860

Q21202901-3344FE84-7263-413C-9245-8BCF06ECE7B5 Q23918083-2747128F-7CA9-49BA-B073-A4D6F211EBB0 Q26774926-F5395AD6-EA47-4174-BBD2-2AF97621107C Q26860736-CFC708A8-3491-47C1-8595-7D76A8B89467 Q28082088-4B02E102-7BFC-4684-9E27-F176388D6CB5 Q28238665-A1D26C5A-730E-4E37-BBEC-A573CD0A2B4C Q28389535-71669EA7-B015-4A1F-907A-6B116888535F Q28394028-4DF31CAE-7095-4CF7-94B4-AF66B7D35897 Q28535472-CC197493-0E47-4212-8EBB-9CA046B83BEB Q33623718-D80422E2-F045-4405-A973-CF70187C7552 Q34278435-86679BA6-4F8B-4F47-90DC-DD2F5F765DD6 Q34441092-736ECFDA-0B5A-45AF-A6FB-83BF0E048A5C Q34646018-9A0C3A73-5B9E-4D13-95EC-D1792599F03A Q34760760-9ACB7201-E25A-4BE5-BCA3-E86894A44DAB Q35021181-74B3F56A-489C-464E-9F4B-072A6DB2BA6E Q35080864-6F948C48-2F9B-49FB-9EC5-C19AC93F8253 Q35558563-2A761258-0302-4B85-B812-A2C3567CB105 Q35904195-80E24CD3-6D79-4F06-A9A4-C32D749FA9B4 Q36199410-A9149103-D55E-4D65-98DA-BA7E3078E31A Q36244087-310FB07D-96D2-4C45-9655-CEA410EEB147 Q36725369-EB04545B-BC4A-452C-B638-A1E4460DBE38 Q37139387-10F08F9F-436D-42C5-8A20-5B53D37F43BD Q37240065-4B9B6772-8E52-4BDD-897B-847E6B8EE7E5 Q37335377-79584008-F490-4836-BB41-4D53DB5FDDDB Q37449036-DFE4941B-8285-4B23-BFDC-5CB7A90CA17D Q37612152-2860F7AA-00A6-4542-96D6-01E64B601ADF Q37862752-530F09D7-EAD8-4399-A8C1-99BAED35C282 Q37975136-F9A2CCF5-1D0B-496D-B930-57F72D62EB8E Q38118298-B1A399C0-1A7B-40AD-8708-32D85031233D Q39124644-84CFC992-B941-413D-ACB0-9DE687AFDCDC Q40809939-06F57B36-70BF-431A-8695-6B3316A70C9C Q40860144-BC20543C-D1BE-4E5C-8153-05C06B31E71B Q41376845-3CDBED5B-2B63-4861-A235-BED45944D4F8 Q41593380-5DBADE87-A0E1-4124-9E22-CAA7563E7660 Q41920935-75A10596-9523-40AB-9F42-7B0CD4A3D884 Q42368993-BDDC1508-B74A-4632-B4A3-60F6A620CBCA Q42650225-05059A17-C743-45A0-800B-8082E34DB559 Q46122543-7B31E211-4AEC-4E0B-ACFC-325A768CE13B Q48367339-191B076F-192C-4F6D-8E7B-4BF3A6DB3BB7 Q51082110-BC77ADDC-C2E0-4EDC-8385-51757DD2AA8D

P2860

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions

http://www.wikidata.org/entity/Q28262540

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@ast

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@en

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@nl

type

label

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@ast

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@en

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@nl

prefLabel

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@ast

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@en

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@nl

P1433

Q28262540-385A3B94-789B-4AC4-9A3D-169783D38B1D

P1476

Q28262540-5FE89C3A-A148-4992-834C-ADE58F7B1B83

P2093

Q28262540-058C673F-BCFF-4423-9043-FA4C46368652

Q28262540-2FDC4CA7-1D75-4376-BC03-00303CBAB84E

Q28262540-3065E56E-DE44-4B0A-91A0-A11EE89EC4F5

Q28262540-372A34E3-2C0B-4034-8CD2-E1045124A2BB

Q28262540-459D302B-BCCC-429F-B2E3-F249C0033A92

Q28262540-52354A98-F6DA-455B-9975-28B3EB674C4A

Q28262540-8A478899-1631-4129-817C-552C4353C343

P304

Q28262540-5E673AAE-7049-477B-9B4A-B4CDAB110ADE

P31

Q28262540-AAD25657-F64B-4FD6-9A4C-46803F1D541F

P3181

Q28262540-6E3DDF09-45E6-40A8-8BC6-8F518C66AF74

P356

Q28262540-A78FD9B3-25B1-4BBF-8983-187627550362

P407

Q28262540-02C99966-B98D-407B-AB26-F095B1884A55

P433

Q28262540-2C391024-DF1C-47B7-80ED-09A28CD5C455

P478

Q28262540-EDF18E0D-CDE7-4F35-936A-594D445162EF

P50

Q28262540-0FC90E1F-A7D3-439F-819C-EEC678A5D4A5

P577

Q28262540-3BCE9DB1-F34A-4769-8689-04E7424E7C7A

P5875

Q28262540-06011729-11A4-47D6-A9F1-93460A2FE066

P698

Q28262540-0D6376C1-D908-4981-BC8F-78F91FF61499

P3181

P356

J.ATHORACSUR.2007.07.042

P1433

The Annals of Thoracic Surgery

P1476

Soluble mesothelin-related pep ...... ma serum and pleural effusions

@en

P2093

Alla Ivanova

http://www.w3.org/2001/XMLSchema#string

Anil Wali

http://www.w3.org/2001/XMLSchema#string

Harvey I Pass

http://www.w3.org/2001/XMLSchema#string

Jeffrey Allard

http://www.w3.org/2001/XMLSchema#string

Michael Harbut

http://www.w3.org/2001/XMLSchema#string

Naimei Tang

http://www.w3.org/2001/XMLSchema#string

Sergey Ivanov

http://www.w3.org/2001/XMLSchema#string

P304

265-72; discussion 272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3625144

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.ATHORACSUR.2007.07.042

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Michele Carbone

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5694018

http://www.w3.org/2001/XMLSchema#string

P698

18154821

http://www.w3.org/2001/XMLSchema#string